Uncategorized - January 13, 2014
Mapping reveals 110 MS-risk genes
Norwegian researchers have mapped genetic variations associated with an increased risk of multiple sclerosis (MS) and myasthenia gravis (MG), bringing science one step closer to understanding these serious autoimmune disorders. The Norwegian researchers have taken part in an international cooperative effort to map 110 genetic variations that increase the risk of MS and MG. Most […]
Drug Development Pharma - January 7, 2014
International pharmaceutical breakthrough backed by public funding
A multi-billion kroner agreement on a new pain-relief medication has been signed between the Norwegian innovation company, Inven2, and the pharmaceuticals giant, Merck. Public funding has played an important role in the Norwegian researchers’ success. The agreement confirms the vast potential of Norwegian health research. There are many outstanding researchers carrying out innovative basic and […]
Drug Development Pharma - December 13, 2013
Bayer granted marketing authorization in Norway for prostate cancer treatment
Bayer HealthCare announced recently that the company has received the marketing approval for Xofigo by the Norwegian Medicines Agency. Xofigo (radium Ra 223 dichloride) has been developed by Algeta. In September 2009, the two companies signed an agreement for the further development and commercialization of radium-223. Xofigo is produced in Norway at the Institute for Energy Technology (IFE) at […]
Clinical Trials - November 1, 2013
Important clinical trials in the North
Three major clinical trials in Norway will help to develop and target treatment and follow-up of patients suffering from COPD, lung cancer and rheumatoid arthritis. At the Norwegian Centre for Integrated Care and Telemedicine in Tromsø in Northern Norway, researchers will be studying the effects of telemedicine on people suffering from chronic obstructive pulmonary disease […]
Uncategorized - October 7, 2013
Individualized cancer treatment
The new Centre for Cancer Biomarkers (CCBIO) at the University of Bergen will conduct in-depth studies of the microenvironment of cancerous tumours, hunting for biomarkers to aid physicians in selecting the best targeted treatment. One of the CCBIO centre’s strengths is that its activities encompass the entire value chain from basic to applied research. Research […]
Uncategorized - September 29, 2013
The Norwegian centre CISMAC will combat threats to women’s and children’s health
The new Centre for Intervention Science in Maternal and Child Health (CISMAC) in Bergen is seeking to find ways to effectively increase survival and enhance maternal and child health. Each year, some seven million children in low- and middle-income countries (LMICs) die before the age of five, and close to 300 000 women lose their […]